Unknown

Dataset Information

0

The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.


ABSTRACT:

Background

Aromatase inhibitors (AIs) substantially reduce breast cancer mortality in clinical trials, but high rates of nonadherence to these long-term oral therapies have reduced their impact outside of trials. We examined the association of generic AI availability with AI adherence among a large national breast cancer cohort.

Methods

Using a quasi-experimental prepost design, we examined the effect of generic AI introductions (7/2010 and 4/2011) on adherence among a national cohort of women with incident breast cancer in 2006 and 2007 who were enrolled in the Medicare D pharmaceutical coverage program. Medicare D claims were used to calculate AI adherence, defined as a medication possession ratio of 80% or more of eligible days, over 36 months. Multivariable logistic regression models estimated with generalized estimating equations were applied to longitudinal adherence data to control for possible confounders, including receipt of a Medicare D low-income subsidy, and to account for repeated measures. All statistical tests were two-sided.

Results

Sixteen thousand four hundred sixty-two Medicare D enrollees were eligible. Adherence declined throughout the study. However, among women without a subsidy, the median quarterly out-of-pocket cost of anastrozole fell from $183 in the fourth quarter of 2009 to $15 in 2011, and declines in adherence were attenuated with generic AI introductions. Regression-adjusted adherence probabilities were estimated to be 5.4% higher after generic anastrozole was introduced in 2010 and 11% higher after generic letrozole/exemestane was introduced in 2011. Subsidy recipients had higher adherence rates throughout the study.

Conclusions

The introduction of generic medications attenuated the decline in adherence to AIs over three years of treatment among breast cancer survivors not receiving low-income subsidies for Medicare D coverage.

SUBMITTER: Neuner JM 

PROVIDER: S-EPMC4580559 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.

Neuner Joan M JM   Kamaraju Sailaja S   Charlson John A JA   Wozniak Erica M EM   Smith Elizabeth C EC   Biggers Alana A   Smallwood Alicia J AJ   Laud Purushottam W PW   Pezzin Liliana E LE  

Journal of the National Cancer Institute 20150512 8


<h4>Background</h4>Aromatase inhibitors (AIs) substantially reduce breast cancer mortality in clinical trials, but high rates of nonadherence to these long-term oral therapies have reduced their impact outside of trials. We examined the association of generic AI availability with AI adherence among a large national breast cancer cohort.<h4>Methods</h4>Using a quasi-experimental prepost design, we examined the effect of generic AI introductions (7/2010 and 4/2011) on adherence among a national co  ...[more]

Similar Datasets

| S-EPMC4915110 | biostudies-literature
| S-EPMC3921685 | biostudies-literature
| S-EPMC4518849 | biostudies-literature
| S-EPMC5803454 | biostudies-other
| S-EPMC4381536 | biostudies-literature
| S-EPMC8576742 | biostudies-literature
| S-EPMC2361690 | biostudies-other
| S-EPMC5764158 | biostudies-literature